Discover and read the best of Twitter Threads about #GIJC
Most recents (5)
@mtahirMD @GiJournal @AGA_Gastro @samirguptaGI @8pm Excellent summary. Imp to note this is one of the studies which contributed to the new USMSTF guidelines.
Q1.Almost the same number of participants ~6k had conventional adenomas and serrated polyps. What accounts for the higher than expected rates of SSPs ? #GIJC @samirguptaGI
Q1.Almost the same number of participants ~6k had conventional adenomas and serrated polyps. What accounts for the higher than expected rates of SSPs ? #GIJC @samirguptaGI
@mtahirMD @GiJournal @AGA_Gastro @samirguptaGI @8pm Q2. Following up on the 1st question.
How does lumping HPs and Serrated lesions together affect the validity of the study? #GIJC @samirguptaGI
How does lumping HPs and Serrated lesions together affect the validity of the study? #GIJC @samirguptaGI
@mtahirMD @GiJournal @AGA_Gastro @samirguptaGI @8pm Q3. How do we know that the low risk of CRC in 1-2 tubular adenoma group is not because of treatment effect/polyp removal?
Wouldn’t this mean that early surveillance is working? #GIJC @samirguptaGI
Wouldn’t this mean that early surveillance is working? #GIJC @samirguptaGI
@GiJournal @AGA_Gastro @samirguptaGI @SultanMahmoodMD @8pm Before we move forward, lets define the polyps: #GIJC 
@GiJournal @AGA_Gastro @samirguptaGI @SultanMahmoodMD @8pm Post-polypectomy surveillance guidelines (for conventional adenomas/SPs) vary widely, and LOE is low. Therefore, the authors performed a prospective study (3 large cohort studies) to correlate the CRC risk with index screening precursors lesions. #GIJC
@GiJournal @SunilAminMD @GIE_Journal @TrieuMD @8pm @gutdoc33 @ealjahdli For @GIJournalClub
❇️@GIE_Journal article: Impact of EUS-guided MFB and nCLE on the diagnostic yield and clinical management of pancreatic cystic lesions.
🔸Expert Opinion: @gutdoc33 @ealjahdli
🔸Moderator: @SunilAminMD @TrieuMD @KM_Pawlak
#GIJC
giejournal.org/article/S0016-…
❇️@GIE_Journal article: Impact of EUS-guided MFB and nCLE on the diagnostic yield and clinical management of pancreatic cystic lesions.
🔸Expert Opinion: @gutdoc33 @ealjahdli
🔸Moderator: @SunilAminMD @TrieuMD @KM_Pawlak
#GIJC
giejournal.org/article/S0016-…
@GiJournal @SunilAminMD @GIE_Journal @TrieuMD @8pm @gutdoc33 @ealjahdli ❇️ Background
Pancreatic cystic lesions (PCLs)
🔹classified into simple retention cysts, pseudocysts and cystic neoplasms
🔹different malignant potential
🔹have varying demographic, morphological, histological and clinical characteristics
🔹various diagnostic modalities for PCL
Pancreatic cystic lesions (PCLs)
🔹classified into simple retention cysts, pseudocysts and cystic neoplasms
🔹different malignant potential
🔹have varying demographic, morphological, histological and clinical characteristics
🔹various diagnostic modalities for PCL
For #GIJournalClub – we will discussing the @NEJM article:
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Background:
- Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
- Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
- Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
- Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
Background – drug mechanisms:
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
Picture credit: nature.com/articles/s4157…
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
Picture credit: nature.com/articles/s4157…
For #GIJournalClub – we will discussing the @NEJM article:
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv
nejm.org/doi/full/10.10…
#livertwitter #GIJC #hpbcsm
Background:
✅ Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
✅ Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
✅ Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo
nejm.org/doi/full/10.10…
Single agent PD-L1 inhibitor w/o improved OS
✅ Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab
sciencedirect.com/science/articl…
Background – drug mechanisms:
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
[Picture credit: nature.com/articles/s4157…]
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor
[Picture credit: nature.com/articles/s4157…]
